Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Stent Stories

2013-03-04 12:28:31

Scottsdale Healthcare is first in region to implant investigational device in patients with clogged arteries SCOTTSDALE, Ariz., March 4, 2013 /PRNewswire-USNewswire/ -- A dissolvable stent that opens clogged arteries in the heart has researchers at Scottsdale Healthcare encouraged that it may become a game changing technology for treating the symptoms of coronary artery disease (CAD), the most common type of heart disease. Interventional cardiologist David Rizik, MD is the first...

2013-02-28 16:28:10

OhioHealth Riverside Methodist Hospital is nation's first to use recently-approved drug-coated stent COLUMBUS, Ohio, Feb. 28, 2013 /PRNewswire/ -- OhioHealth Riverside Methodist Hospital is now treating patients with peripheral artery disease (PAD) with the first drug-eluting stent to be used outside of the heart. Cook Medical's Zilver PTX is a drug-coated stent that is used to reopen a long thigh artery, located above the knee (the femoropopliteal artery), narrowed or blocked due...

2013-02-23 23:03:16

According to a new market report published by Transparency Market Research "Interventional Cardiology Devices Market (Bare Metal/Drug Eluting/Bio-absorbable Stents, PTCA Balloons, Scoring Balloons, Guidewires, Guiding Catheters, Angiography Catheters, IVUS, Balloon Inflation Devices) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018," the global market for interventional cardiology devices was calculated at USD 15.8 billion in 2011 and is expected to grow at a CAGR of...

2013-02-20 08:27:40

FORT LAUDERDALE, Fla., Feb. 20, 2013 /PRNewswire/ -- OrbusNeich today announced that OrbusNeich Medical GmbH and Orbus International B.V., subsidiaries of OrbusNeich Medical, Inc., (collectively, "OrbusNeich") have commenced patent infringement actions in Germany and The Netherlands against Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific") and its distribution affiliates in those countries. The Complaints allege that Boston Scientific infringed two European patents covering...

2013-02-19 08:33:20

Breakthrough in Vascular Surgery Provides Enhanced Safety and Faster Recovery for Patients with Complex Aneurysms LAGUNA HILLS, Calif., Feb. 19, 2013 /PRNewswire-USNewswire/ -- Innovations in patient care at the Heart and Vascular Institute at Saddleback Memorial took another leap forward with the completion of the first surgery in Orange County using the Zenith® Fenestrated AAA Endovascular Graft. This new technology is the newest generation of minimally-invasive treatment...

2013-02-19 04:22:57

ALBANY, New York, February 19, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Interventional Cardiology Devices Market (Bare Metal/Drug Eluting/Bio-absorbable Stents, PTCA Balloons, Scoring Balloons, Guidewires, Guiding Catheters, Angiography Catheters, IVUS, Balloon Inflation Devices) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018," the global market for...

2013-02-12 08:31:56

NATICK, Mass., Feb. 12, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES) technology, and is starting its European market launch. The Promus PREMIER Stent System is designed to provide physicians improved DES performance in treating patients with coronary artery disease. It is the only...

2013-02-12 08:29:29

FORT LAUDERDALE, Fla., Feb. 12, 2013 /PRNewswire/ -- OrbusNeich Medical, Inc. ("OrbusNeich") announced that it received a favorable ruling from the European Patent Office ("EPO") yesterday in connection with its European Patent EP1 341 482. The '482 patent covers certain novel stents with helical structures. It was issued by the EPO to OrbusNeich in October 2010 and does not expire until December 2021. In July 2011, Boston Scientific Corporation (NYSE: BSX) and Terumo Kabushiki Kaisha...

2013-02-11 08:26:23

TEL AVIV, Israel, February 11, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (OTC: NSPRD) announced that Michael Berman joined its board of directors. Mr. Berman previously served as a Senior Vice President of Boston Scientific Corp., Group President of its cardiology businesses, and a member of the Executive Committee. Since leaving Boston Scientific, Mr. Berman co-founded or was a founding director of seven medical technology companies,...

2013-02-05 08:35:18

HAMBURG, Germany, February 5, 2013 /PRNewswire/ -- It is estimated that the global interventional peripheral device market will exceed 4 Billion euros by 2015. The three largest portions of this market ranked in order based on global market size are: 1) Peripheral Vascular Stents which account for approximately 34% of the market 2) PTA Balloon Catheters representing the 2nd largest market segment 3) Aortic Stent Graft claiming the...


Latest Stent Reference Libraries

Interventional Radiology
2013-03-04 16:18:42

Interventional radiology (IR) is a special sub-operation under general radiology. It is used to find, diagnose and treat a disease in almost every body system. The process of interventional radiology is very noninvasive to help with the recovery and outcome of the procedure. It utilizes x-rays, CT, ultrasound, MRI, and other modes of imaging in order to direct tools in the body as well as a variety of catheters, narrow tubes, so that incisions can be minimalized. How it is Performed...

More Articles (1 articles) »